Early safety results promising for Phase I/II trial of gene therapy treatment of he... ( Investigators report no evidence of ...)

Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B

Date:12/6/2010

Investigators report no evidence of toxicity in the four hemophilia B patients enrolled to date in a gene therapy trial using a vector under development at St. Jude Children's Research Hospital and UCL (University College London) to correct the inherited bleeding disorder.

This trial was designed primarily as a safety test, with low and intermediate doses of the vector expected to produce little detectable Factor IX. The Factor IX protein helps the blood form clots. Individual with hemophilia B lack adequate levels of this clotting factor. The first participant in the open-label Phase I/II trial had an unexpectedly high level of Factor IX expression after receiving the lowest dose of the vector being tested in this study. Levels of the Factor IX protein rose from less than 1 percent to 2 percent of normal after the experimental vector was infused into the patient.

The patient's Factor IX production remains elevated more than nine months later. Since the infusion the patient has also not suffered any spontaneous joint bleeds or needed prophylactic treatment.

Study data was presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) by Amit Nathwani, M.D., Ph.D., UCL Department of Hematology, and National Health Service Blood and Transplant, UK, the study's first author. Andrew Davidoff, M.D., chair of the St. Jude Department of Surgery, is the senior author.

Work on the vector began more than 10 years ago in the St. Jude laboratory of Arthur Nienhuis, M.D., member of the Department of Hematology and a study co-author. The collaboration continued after Nathwani returned to London.

The trial vector was made by packaging a codon-optimized version of the Factor IX gene into a member of the adeno-associated virus (AAV) family known as AAV8. AAV8 was picked because the incidence of natural infection with AAV8 is low and, like other AAVs, targets liver cells but does not integrate into the patient's
'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

0

GOOD

Page: 1 2
Related biology news :

1. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
2. U of M researcher helps unlock 30 new genes responsible for early onset puberty
3. UGA researchers identify key enzyme that regulates the early growth of breast cancer cells
4. PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years
5. Arsenic early in treatment improves survival for leukemia patients
6. Brookhaven chemist Jacob Hooker receives Presidential Early Career Award
7. Studying the metabolome of smokers, Lombardi researchers find early signs of damage
8. UV light nearly doubles vacuums effectiveness in reducing carpet microbes
9. Found: First complete remains of early sauropod dinosaur
10. Early role of mitochondria in AD may help explain limitations to current beta amyloid hypothesis
11. JCI online early table of contents: Oct. 11, 2010

Post Your Comments:

(Date:6/18/2013)... the United Kingdom, the Energy Department,s National Renewable ... have recently published a paper describing a novel ... Limnoria quadripunctata , commonly known as the gribble. ... exhibit a relatively unique ability to produce their ... break down the biomass they eat. New biomass-degrading ...

(Date:6/18/2013)... Research Council, Laboratory of Molecular Biology, has been ... Young Investigator Award. Torrent is being recognized for ... algorithm to predict antimicrobial regions in proteins. Luis ... now applying this algorithm to interrogate full genomes ... with very appealing results." , Torrent obtained ...

(Date:6/18/2013)... 18, 2013 The herbal extract of a yellow-flowered ... to increase the lifespan of fruit fly populations by ... researchers. , But it,s how Rhodiola ... that grabbed the attention of study leaders Mahtab Jafari ... works in a manner completely unrelated to dietary restriction ...

Breaking Biology News(10 mins):Novel enzyme from tiny gribble could prove a boon for biofuels research 2 The American Society for Microbiology honors Marc Torrent 2 Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2

[0] Novel enzyme from tiny gribble could prove a boon for biofuels research [0] The American Society for Microbiology honors Marc Torrent [0] Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds

... In nature, ultraviolet radiation from sunlight is not the ... and females who choose to lay their eggs in the ... amphibian species out of harm,s way most of the time, ... of the long-toed salamander received lethal doses of UV across ...

... Researchers from the p53 Laboratory of Singapore,s Agency for ... makes feasible a unique method of cancer treatment. Their work, ... Differentiation today , offers new insight on how to ... genome, , to more effectively kill cancer cells while sparing ...

... 2010) - A technique pioneered in the Tissue Engineering ... Edward V. Zegarelli Professor of Dental Medicine at Columbia ... to a three-dimensional scaffold infused with growth factor, holding ... in as soon as nine weeks once implanted. ...

Cached Biology News:Ultraviolet radiation not culprit killing amphibians, research shows 2 Ultraviolet radiation not culprit killing amphibians, research shows 3 Singapore scientists exploit knowledge of p53 for increasing specificity of cancer treatments 2 Technique yields potential biological substitute for dental implants 2

Ultraviolet radiation not culprit killing amphibians, research shows Singapore scientists exploit knowledge of p53 for increasing specificity of cancer treatments Technique yields potential biological substitute for dental implants

(Date:6/19/2013)... Washington (PRWEB) June 18, 2013 A ... complex materials, costs and other trends will highlight technical ... Monterey, California this fall. In its 33rd year, the ... includes an exhibition of key suppliers, approximately 100 technical ... SPIE, the international society for optics and photonics ...

(Date:6/18/2013)... 18, 2013 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its preliminary unaudited financial results for the fourth ... March 31, 2013. Fourth Quarter of ... quarter of fiscal 2013 increased by 33.3% to RMB133.0 ...

(Date:6/18/2013)... The human skin is the largest organ, ... human body part. Similar to the liver, or heart, the ... repair and grow. Recent reports from the mankatofreepress.com explained how ... as important as other life supporting organs. The article suggests ... cell reproduction, increase the appearance of skin, and fight off ...

(Date:6/18/2013)... 2013 regulated information — Global biopharmaceutical company UCB, ... announced the launch of a new Pledge campaign for ... The Pledge empowers the millions of Americans ... a personal commitment to demand more: greater understanding of ... and additional partial-onset seizure control. More information is available ...

[0] ‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin [0] Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy

... 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ... his research group at The Institute of Cancer ... testing combination treatment schedules,of reovirus and radiation in ... in,vivo. The paper, entitled "Enhanced In vitro and ...

... 2008) -- A University of Waterloo physics and astronomy ... in Science Magazine, shows how some solids behave like ... James Forrest and then-graduate student Zahra Fakhraai, take a ... substances using nanoscale technology. , They explore the properties ...

... 1 MannKind Corporation,(Nasdaq: MNKD ), focused on ... today that it will present at,the Merrill Lynch Global ... at 1:40 PM ET at the Grand Hyatt Hotel ... link to the live web cast of the,presentation in ...

Cached Biology Technology:Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy 2 UW paper in Science shows how some solids mimic liquids on nanoscale 2

Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy UW paper in Science shows how some solids mimic liquids on nanoscale MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

Anti-TWIK-1 Immunogen: Purified peptide from amino acids 53-69 of human TWIK-1 (Accession number O00180)....

Monoclonal 8C2.1 is specific for Bunyavirus G1 as tested by neutralization, immunoprecipitation and immunobinding assays....

BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...

...

Biology Products:

Rabbit Anti-TWIK-1 Antibody, Unconjugated from CHEMICON Anti-Bunyavirus (G1) Monoclonal Antibody, Unconjugated, Clone 8C2.1 from CHEMICON Rabbit Anti-BI-1 Polyclonal Antibody, Unconjugated from BioVision Capped Xef-1 RNA 0.05 ml from Ambion